

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**


- [C1]** (Cancelled) Use of IG20 or at least one of its splice variants or a fragment thereof to regulate cell death or cell replication.
- [C2]** (Cancelled) The use of claim 1, wherein IG20 or at least one of its splice variants is expressed to a higher than normal level.
- [C3]** (Cancelled) The use of claim 1, wherein IG20 or at least one of its splice variants or a fragment thereof is used to regulate tumor cell death or replication.
- [C4]** (Cancelled) The use of claim 1, wherein IG20 or at least one of its splice variants or a fragment thereof makes cells more sensitive to induced cell death.
- [C5]** (Cancelled) The use of claim 1, wherein cell death is induced by radiation.
- [C6]** (Cancelled) The use of claim 1, wherein cell death is induced by chemotherapy.
- [C7]** (Cancelled) The use of claim 3, wherein the tumor cells are cancer cells.
- [C8]** (Cancelled) Use of DENN-SV or at least one of its splice variants or a fragment thereof to regulate cell death or cell replication.
- [C9]** (Cancelled) Use of an anti-sense molecule of DENN-SV or a fragment thereof to promote cell death or suppress cell replication.
- [C10]** (Cancelled) Use of Si RNA of DENN-SV or a fragment thereof to promote cell death or suppress cell replication.
- [C11]** (Cancelled) The use of claim 8, wherein DENN-SV or at least one of its splice variants or a fragment thereof is used to promote growth of cells or to maintain cells alive.
- [C12]** (Cancelled) The use of claim 8, wherein the cell is selected from the group of primary cells consisting of insulin producing cells, neuronal cells, and stem cells.
- [C13]** (Cancelled) The use of claim 8, wherein cell replication is suppressed in tumor cells.
- [C14]** (Cancelled) The use of claim 1, wherein cell death is induced by a ligand that binds to a death receptor.
- [C15]** (Cancelled) The use of claim 14, wherein the death receptor is selected from the group consisting of FAS-ligand, TNF-alpha, TRAIL, or anti-receptor antibodies.

- [C16]** (Cancelled) Use of an antibody of IG20 or DENN-SV or at least one of its splice variants or a fragment thereof to regulate cell death or cell replication.
- [C17]** (Cancelled) A method to modulate levels of IG20 or DENN-SV to regulate cell death or cell proliferation, the method comprising:
- (a) providing a molecule to regulate endogenous levels of IG20 or at least one of its splice variants or DENN-SV or at least one of its splice variants; and
  - (b) monitoring the endogenous levels of IG20 or at least one of its splice variants or DENN-SV or at least one of its splice variants.
- [C18]** (Cancelled) The method of claim 17, wherein the molecule is selected from the group consisting of a chemical regulator, genetic sequence, cDNA, oligonucleotide, protein, peptide or fragments thereof, and antibodies.
- [C19]** (Cancelled) IG20 molecule or its splice variant having an amino acid sequence encoded by nucleic acid sequences represented by GenBank accession numbers AF440100, AF440101, AF440102, AF440103, AF440434.
- [C20]** (Cancelled) IG20 molecule or its splice variant having an amino acid sequence encoded by nucleic acid sequences represented by GenBank accession numbers AY263980, AY263981, AY263982, AY263983, AY263984, AY263985, AY263986, AY263988 and AY263989.
- [C21]** (New) A method to regulate cell death and cell replication by modulating expression of human splice variants of *IG20* in the cell, the method comprising:
- (a) increasing cell replication by increasing splice variant DENN-SV to increase cell replication; and
  - (b) increasing cell death and slowing cell growth by increasing splice variant IG20.
- [C22]** (New) The method of claim 21 wherein cells provided with DENN-SV are resistant to inducers of cell death, and cells provided with IG20 are susceptible to inducers of cell death.
- [C23]** (New) The method of claim 21 wherein cells treated with inhibitors of splice variant DENN-SV or with increased IG20 undergo cell death.

- [C24]** The method of claim 21 wherein cell death and cell replication are modulated in cancer cells.
- [C25]** The method of claim 22, wherein inducers of cell death are selected from the group consisting of radiation and chemotherapy.
- [C26]** The method of claim 22 wherein the inhibitors are selected from a group consisting of siRNA, antisense molecules and antibodies.

No other fees are believed due at this time, however, please charge any deficiencies or credit any overpayments to deposit account number 12-0913 with reference to our attorney docket number (21726/97440).

Respectfully Submitted,

A handwritten signature in cursive script, appearing to read "Alice O. Martin".

Alice O. Martin  
Attorney for Applicants  
Registration No. 35,601

Dated: March 20, 2006  
Barnes & Thornburg  
Suite 4400  
One North Wacker Drive  
Chicago, Illinois 60606-2809  
Phone: 312-214-8316  
Fax: 312-759-5646

CHDS01 AOM 169914v1